Evidence map›Paper›PMID 36803547›Full record

SynthesisBiomolecules & biomedicine2023

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases.

Pandit Bagus Tri Saputra, Roy Bagus Kurniawan, Desy Trilistyoati, Makhyan Jibril Al Farabi, Hendri Susilo, Mochamad Yusuf Alsagaff, Yudi Her Oktaviono, Henry Sutanto, Arief Gusnanto, Citrawati Dyah Kencono Wungu

Abstract readSystematic Review
In one paragraph

Synthesis in Biomolecules & biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pandit Bagus Tri SaputraDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr Soetomo General Academic Hospital, Surabaya, Indonesia.
Roy Bagus KurniawanFaculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Desy TrilistyoatiFaculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Makhyan Jibril Al FarabiDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr Soetomo General Academic Hospital, Surabaya, Indonesia.
Hendri SusiloDepartment of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia.
Mochamad Yusuf AlsagaffDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr Soetomo General Academic Hospital, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia.
Yudi Her OktavionoDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr Soetomo General Academic Hospital, Surabaya, Indonesia.
Henry SutantoDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, ‎Netherlands.
Arief GusnantoSchool of Mathematics, University of Leeds, Leeds, UK.
Citrawati Dyah Kencono WunguDepartment of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is significant to control, mitigate, and recover from the destructive effects of coronavirus disease 2019 (COVID-19). The incidence of myocarditis following COVID-19 vaccination has been increasing and growing public concern; however, little is known about it. This study aimed to systematically review myocarditis following COVID-19 vaccination. We included studies containing individual patient data of myocarditis following COVID-19 vaccination published between January 1, 2020 and September 7, 2022 and excluded review articles. Joanna Briggs Institute critical appraisals were used for risk of bias assessment. Descriptive and analytic statistics were performed. A total of 121 reports and 43 case series from five databases were included. We identified 396 published cases of myocarditis and observed that the majority of cases was male patients, happened following the second dose of mRNA vaccine administration, and experienced chest pain as a symptom. Previous COVID-19 infection was significantly associated (p < 0.01; OR, 5.74; 95% CI, 2.42-13.64) with the risk of myocarditis following the administration of the first dose, indicating that its primary mechanism is immune-mediated. Moreover, 63 histopathology examinations were dominated by non-infective subtypes. Electrocardiography and cardiac marker combination is a sensitive screening modality. However, cardiac magnetic resonance is a significant noninvasive examination to confirm myocarditis. Endomyocardial biopsy may be considered in confusing and severe cases. Myocarditis following COVID-19 vaccination is relatively benign, with a median length of hospitalization of 5 days, intensive care unit admission of <12%, and mortality of <2%. The majority was treated with nonsteroidal anti-inflammatory drugs, colchicine, and steroids. Surprisingly, deceased cases had characteristics of being female, older age, non-chest pain symptoms, first-dose vaccination, left ventricular ejection fraction of <30%, fulminant myocarditis, and eosinophil infiltrate histopathology.

Indexed as

COVID-19COVID-19 VaccinesMyocarditisChest PainFemaleHumansMaleStroke VolumeVentricular Function, LeftCOVID-19 Vaccines

Identifiers

PMID36803547
PMCPMC10351100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.